Aclaris Therapeutics, Inc. Insider Trading

ACRS

⊜ Compare

Last 12 months

No open-market buying or selling by insiders.

The last open-market buy by an executive or director was in Nov 2024.

Net open-market

0 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

0 / 0

executives and directors

Last open-market buy

Nov 2024

Nov 19, 2024

Get an email when ACRS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Apr 23	Braden Michael Leonard Large holder	SoldNo plan	300,000	$4.53	$1.36M	2.1%	Form 4
Nov 19, 2024	Anand Mehra Director	Bought	666,666	$2.25	$1.5M	1537%	Form 4

Apr 23No plan
Braden Michael Leonard
Large holder · sold 300,000 at $4.53
$1.36M
2.1% of stake
Nov 19, 2024
Anand Mehra
Director · bought 666,666 at $2.25
$1.5M
1537% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ACRS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ACRS

CompareIntrinsic value

ROIVRoivant Sciences Ltd

$38.23+6.08%16

ALMSAlumis Inc.

$6.55+0.77%10

COYACoya Therapeutics Inc.

$3.08-0.96%10

ADAGAdagene Inc.

$2.41+2.55%25

KYNBKyntra Bio, Inc.

$3.96-8.12%20

ISCOInternational Stem Cell Corporation

$0.14+0.00%29

OVIDOvid Therapeutics Inc.

$2.74+14.17%25

NAMSNewAmsterdam Pharma Co. N.V.

$20.93+5.18%10

Held by ETFs

ACRS is in 18 US ETFs. The largest of them, with ACRS's weight in each:

Spot a number that looks wrong? Check it in ACRS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ACRS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.